| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
864,930 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
39,326 |
449,967 |
| Total Sell Value |
$0 |
$0 |
$8,245,949 |
$81,866,696 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
18 |
69 |
| End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Simpson Todd E |
Chief Financial Officer |
• – – |
2011-05-18 |
4 |
OE |
$4.45 |
$105,110 |
D/D |
21,250 |
16,546 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2011-05-13 |
4 |
AS |
$17.80 |
$356,000 |
D/D |
(20,000) |
3,027 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2011-05-13 |
4 |
OE |
$8.24 |
$164,800 |
D/D |
20,000 |
8,027 |
|
- |
|
| Rosenberg Morris |
EVP, Process Sciences |
• – – |
2011-05-13 |
4 |
AS |
$17.80 |
$356,000 |
D/D |
(20,000) |
0 |
|
- |
|
| Rosenberg Morris |
EVP, Process Sciences |
• – – |
2011-05-13 |
4 |
OE |
$6.34 |
$126,800 |
D/D |
20,000 |
20,000 |
|
- |
|
| Dobmeier Eric |
Chief Business Officer |
• – – |
2011-05-13 |
4 |
AS |
$18.00 |
$768,870 |
D/D |
(42,715) |
25,802 |
|
- |
|
| Dobmeier Eric |
Chief Business Officer |
• – – |
2011-05-13 |
4 |
OE |
$5.81 |
$251,382 |
D/D |
42,715 |
54,967 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2011-05-09 |
4 |
AS |
$17.74 |
$354,800 |
D/D |
(20,000) |
9,359 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2011-05-09 |
4 |
OE |
$4.45 |
$89,000 |
D/D |
20,000 |
29,359 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2011-05-09 |
4 |
AS |
$17.35 |
$867,705 |
D/D |
(50,000) |
945,667 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2011-05-09 |
4 |
OE |
$8.43 |
$421,500 |
D/D |
50,000 |
995,667 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2011-05-02 |
4 |
AS |
$17.43 |
$871,355 |
D/D |
(50,000) |
945,667 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2011-05-02 |
4 |
OE |
$8.43 |
$421,500 |
D/D |
50,000 |
995,667 |
|
- |
|
| Rosenberg Morris |
EVP, Process Sciences |
• – – |
2011-05-02 |
4 |
AS |
$17.50 |
$218,751 |
D/D |
(12,500) |
0 |
|
- |
|
| Rosenberg Morris |
EVP, Process Sciences |
• – – |
2011-05-02 |
4 |
OE |
$6.72 |
$84,000 |
D/D |
12,500 |
12,500 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2011-04-29 |
4 |
AS |
$16.94 |
$254,100 |
D/D |
(15,000) |
9,359 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2011-04-29 |
4 |
OE |
$4.45 |
$66,750 |
D/D |
15,000 |
24,359 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2011-04-29 |
4 |
AS |
$16.95 |
$201,959 |
D/D |
(11,915) |
3,027 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2011-04-29 |
4 |
OE |
$8.24 |
$82,392 |
D/D |
9,999 |
6,360 |
|
- |
|
| Rosenberg Morris |
EVP, Process Sciences |
• – – |
2011-04-29 |
4 |
AS |
$16.80 |
$210,000 |
D/D |
(12,500) |
0 |
|
- |
|
| Rosenberg Morris |
EVP, Process Sciences |
• – – |
2011-04-29 |
4 |
OE |
$6.72 |
$84,000 |
D/D |
12,500 |
12,500 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2011-04-14 |
4 |
AS |
$15.27 |
$763,455 |
D/D |
(50,000) |
945,667 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2011-04-14 |
4 |
OE |
$8.43 |
$421,500 |
D/D |
50,000 |
995,667 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2011-04-07 |
4 |
AS |
$16.06 |
$802,905 |
D/D |
(50,000) |
945,667 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2011-04-07 |
4 |
OE |
$8.43 |
$421,500 |
D/D |
50,000 |
995,667 |
|
- |
|
1805 Records found
|
|
Page 52 of 73 |
|
|
